Loading
FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.
Key enzyme in isoprenoid biosynthesis which catalyses the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyses the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.86, genetic association 0.00, clinical 0.99).
In plain words · FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.
FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.
Key enzyme in isoprenoid biosynthesis which catalyses the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones.
No product in this corpus aims at FDPS yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA lists FDPS among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA FDPS: RNA tissue enhanced (liver 333 nTPM); no normal tissue stained high; highest cancer staining liver cancer (2 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Prostate cancer, Multiple myeloma, Breast cancer (all types)); Open Targets associates it with 5 specific cancer types at or above 0.5 (plasma cell myeloma, prostate carcinoma, prostate cancer, Paget disease, breast cancer). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FDPS tissue; Open Targets ENSG00000160752 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Sheares B.T. et al, Biochemistry, 1989, "Cloning, analysis, and bacterial expression of human farnesyl pyrophosphate synthetase and its regulation in Hep G2 cells". Source.
Sources: HGNC HGNC:3631 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P14324 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000160752 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: prostate cancer 0.60, plasma cell myeloma 0.60, breast cancer 0.54 (GraphQL API, CC0))
Key enzyme in isoprenoid biosynthesis which catalyses the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyses the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate. Location: Cytoplasm (UniProt). Locus 1q22 (HGNC).
RNA: tissue enhanced (liver 333 nTPM), detected in all normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Breast, Bronchus, Cerebral cortex, Duodenum and more.
Medium only: pancreatic cancer, stomach cancer, urothelial cancer.
HPA FDPS tissue · HPA FDPS pathology · HPA protein class: Essential proteins, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FDPS" OR ABSTRACT:"FDPS" OR TITLE:"farnesyl diphosphate synthase" OR ABSTRACT:"farnesyl diphosphate synthase" OR TITLE:"Farnesyl pyrophosphate synthase" OR ABSTRACT:"Farnesyl pyrophosphate synthase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FDPS, not a curated reading list.